| 20.01 0 (0%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing groundbreaking therapies for rare hematologic conditions and various cancers. Its lead development candidates include FT-4202, undergoing Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. The company is also progressing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 (IDH1) gene mutations, currently in Phase II for relapsed/refractory acute myeloid leukemia and Phase I for glioma. Furthermore, Forma is developing FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to disrupt de novo lipogenesis in the liver. Founded in 2007 and headquartered in Watertown, Massachusetts, Forma Therapeutics Holdings, Inc. has operated as a subsidiary of Novo Nordisk A/S since October 14, 2022.
Sun, 20 Aug 2023
Vickers Selwyn M Md Net Worth (2026) - GuruFocus
Fri, 16 Dec 2022
The top 10 pharma M&A deals of 2022 - drugdiscoverytrends.com
Fri, 30 Sep 2022
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease - Business Wire
Thu, 01 Sep 2022
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout - Investor's Business Daily
Thu, 01 Sep 2022
Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion - Pulse 2.0
Thu, 01 Sep 2022
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|